Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Substrates and Inhibitors of SAMHD1.

Hollenbaugh JA, Shelton J, Tao S, Amiralaei S, Liu P, Lu X, Goetze RW, Zhou L, Nettles JH, Schinazi RF, Kim B.

PLoS One. 2017 Jan 3;12(1):e0169052. doi: 10.1371/journal.pone.0169052. eCollection 2017.

2.

Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.

Stanton RA, Lu X, Detorio M, Montero C, Hammond ET, Ehteshami M, Domaoal RA, Nettles JH, Feraud M, Schinazi RF.

Bioorg Med Chem Lett. 2016 Aug 15;26(16):4101-5. doi: 10.1016/j.bmcl.2016.06.065. Epub 2016 Jun 25.

PMID:
27390064
3.

Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.

Stanton RA, Nettles JH, Schinazi RF.

J Mol Model. 2015 Nov;21(11):282. doi: 10.1007/s00894-015-2826-7. Epub 2015 Oct 8.

PMID:
26450349
4.

Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.

Boucle S, Tao S, Amblard F, Stanton RA, Nettles JH, Li C, McBrayer TR, Whitaker T, Coats SJ, Schinazi RF.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3711-5. doi: 10.1016/j.bmcl.2015.06.031. Epub 2015 Jun 15.

5.

Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.

Nettles JH, Stanton RA, Broyde J, Amblard F, Zhang H, Zhou L, Shi J, McBrayer TR, Whitaker T, Coats SJ, Kohler JJ, Schinazi RF.

J Med Chem. 2014 Dec 11;57(23):10031-43. doi: 10.1021/jm501291c. Epub 2014 Nov 3.

6.

Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF.

Infect Drug Resist. 2014 Mar 5;7:41-56. doi: 10.2147/IDR.S36247. eCollection 2014. Review.

7.

Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.

Wadford DA, Kauffman RC, Deere JD, Aoki ST, Stanton RA, Higgins J, Van Rompay KK, Villalobos A, Nettles JH, Schinazi RF, Pedersen NC, North TW.

PLoS One. 2014 Jan 31;9(1):e86997. doi: 10.1371/journal.pone.0086997. eCollection 2014.

8.

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.

Amblard F, Zhang H, Zhou L, Shi J, Bobeck DR, Nettles JH, Chavre S, McBrayer TR, Tharnish P, Whitaker T, Coats SJ, Schinazi RF.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2031-4. doi: 10.1016/j.bmcl.2013.02.023. Epub 2013 Feb 13.

9.

Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs.

Herman BD, Schinazi RF, Zhang HW, Nettles JH, Stanton R, Detorio M, Obikhod A, Pradère U, Coats SJ, Mellors JW, Sluis-Cremer N.

Nucleic Acids Res. 2012 Jan;40(1):381-90. doi: 10.1093/nar/gkr756. Epub 2011 Sep 13.

10.

Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.

Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF.

Eur J Med Chem. 2011 Sep;46(9):3832-44. doi: 10.1016/j.ejmech.2011.05.051. Epub 2011 May 30.

11.

Drugs that target dynamic microtubules: a new molecular perspective.

Stanton RA, Gernert KM, Nettles JH, Aneja R.

Med Res Rev. 2011 May;31(3):443-81. doi: 10.1002/med.20242. Epub 2011 Mar 4. Review.

12.

Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase.

Schinazi RF, Massud I, Rapp KL, Cristiano M, Detorio MA, Stanton RA, Bennett MA, Kierlin-Duncan M, Lennerstrand J, Nettles JH.

Antimicrob Agents Chemother. 2011 May;55(5):2054-60. doi: 10.1128/AAC.01700-10. Epub 2011 Feb 28.

13.

Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.

Sharma PL, Nettles JH, Feldman A, Rapp K, Schinazi RF.

Antiviral Res. 2009 Sep;83(3):317-23. doi: 10.1016/j.antiviral.2009.06.002. Epub 2009 Jun 23.

14.

The tubulin binding mode of microtubule stabilizing agents studied by electron crystallography.

Nettles JH, Downing KH.

Top Curr Chem. 2009;286:209-57. doi: 10.1007/128_2008_24.

PMID:
23563614
15.

Approaches for the development of antiviral compounds: the case of hepatitis C virus.

Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ.

Handb Exp Pharmacol. 2009;(189):25-51. doi: 10.1007/978-3-540-79086-0_2. Review.

PMID:
19048196
16.

Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data.

Crisman TJ, Parker CN, Jenkins JL, Scheiber J, Thoma M, Kang ZB, Kim R, Bender A, Nettles JH, Davies JW, Glick M.

J Chem Inf Model. 2007 Jul-Aug;47(4):1319-27. Epub 2007 Jul 4.

PMID:
17608469
17.

"Plate cherry picking": a novel semi-sequential screening paradigm for cheaper, faster, information-rich compound selection.

Crisman TJ, Jenkins JL, Parker CN, Hill WA, Bender A, Deng Z, Nettles JH, Davies JW, Glick M.

J Biomol Screen. 2007 Apr;12(3):320-7.

PMID:
17438067
18.

Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.

Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI.

Mol Cancer Ther. 2007 Apr;6(4):1317-28.

19.

Flexible 3D pharmacophores as descriptors of dynamic biological space.

Nettles JH, Jenkins JL, Williams C, Clark AM, Bender A, Deng Z, Davies JW, Glick M.

J Mol Graph Model. 2007 Oct;26(3):622-33. Epub 2007 Mar 1.

PMID:
17395510
20.

Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors.

Nettles JH, Jenkins JL, Bender A, Deng Z, Davies JW, Glick M.

J Med Chem. 2006 Nov 16;49(23):6802-10.

PMID:
17154510
21.

"Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?

Bender A, Jenkins JL, Glick M, Deng Z, Nettles JH, Davies JW.

J Chem Inf Model. 2006 Nov-Dec;46(6):2445-56.

PMID:
17125186
22.

Rational design of the microtubule-targeting anti-breast cancer drug EM015.

Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, Yao J, Nettles JH, Zhou B, Gupta M, Panda D, Chandra R, Joshi HC.

Cancer Res. 2006 Apr 1;66(7):3782-91.

23.

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.

Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM.

Mol Cancer Ther. 2006 Feb;5(2):270-8.

24.
25.

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography.

Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH.

Science. 2004 Aug 6;305(5685):866-9.

26.

Microtubule-interacting drugs for cancer treatment.

Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC.

Trends Pharmacol Sci. 2003 Jul;24(7):361-5. Review. No abstract available.

PMID:
12871669
27.

Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition.

Judd DA, Nettles JH, Nevins N, Snyder JP, Liotta DC, Tang J, Ermolieff J, Schinazi RF, Hill CL.

J Am Chem Soc. 2001 Feb 7;123(5):886-97.

PMID:
11456622
28.

The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density.

Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5312-6. Epub 2001 Apr 17.

Supplemental Content

Loading ...
Support Center